Bio News
Ipsel announced the 1-year follow-up results from a domestic clinical study of Mucon, a cartilage cell therapy. No serious adverse reactions were observed after administration to 3 patients with knee osteoarthritis. Serial MRI scans confirmed a reduction in the cartilage defect area and a pattern of cartilage thickness recovery in the damaged area.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
